Grepid (Clopidogrel)

Grepid is prescribed for several antithrombotic indications where prevention of platelet‑driven clot formation is essential.

• Prevention of atherothrombotic events in patients with a prior myocardial infarction, ischemic stroke, or established peripheral arterial disease.
• Secondary prevention after an acute coronary syndrome, including unstable angina or non‑ST‑segment elevation myocardial infarction.
• Reduction of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) with stent placement.
• Use in combination with aspirin for dual antiplatelet therapy when indicated by clinical guidelines.

The safety profile of Grepid includes a range of adverse reactions that vary in frequency and severity.

Common

• Minor bleeding such as gum bleeding, nosebleeds, or easy bruising.
• Gastrointestinal discomfort, including nausea or dyspepsia.
• Headache or dizziness.
• Diarrhea or abdominal pain.

Serious

• Severe or uncontrolled bleeding, including intracranial hemorrhage.
• Thrombotic thrombocytopenic purpura (TTP).
• Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Grepid, clinicians should evaluate several clinical factors to ensure safe use.

• Assess patient history for active bleeding or high bleeding risk.
• Review liver function, as hepatic impairment may affect drug metabolism.
• Consider renal function, especially in patients with severe chronic kidney disease.
• Evaluate for known hypersensitivity to clopidogrel or any component of the formulation.
• Use caution in patients receiving concurrent anticoagulants or antiplatelet agents.
• Counsel women of childbearing potential about unknown pregnancy safety.
• Discontinue before surgical procedures according to recommended timing.

Grepid can interact with other medicines, influencing either its antiplatelet effect or the effect of the co‑administered drug.

Avoid

• Concurrent use with strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole) that may reduce conversion to the active metabolite.
• Combination with other antiplatelet agents (e.g., ticagrelor, prasugrel) that markedly increase bleeding risk.
• Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants (warfarin, DOACs) when uncontrolled bleeding must be avoided.

Use with caution

• Co‑administration with proton pump inhibitors that have moderate CYP2C19 inhibition (e.g., pantoprazole).
• Concomitant use of selective serotonin reuptake inhibitors (SSRIs) which may increase bleeding tendency.
• Combination with glycoprotein IIb/IIIa inhibitors during PCI procedures.